PuSH - Publikationsserver des Helmholtz Zentrums München

Steenblock, C.* ; Schwarz, P.E. ; Ludwig, B. ; Linkermann, A.* ; Zimmet, P.* ; Kulebyakin, K.* ; Tkachuk, V.A.* ; Markov, A.G.* ; Lehnert, H.* ; Hrabě de Angelis, M. ; Rietzsch, H.* ; Rodionov, R.N.* ; Khunti, K.* ; Hopkins, D.* ; Birkenfeld, A.L. ; Boehm, B.* ; Holt, R.I.G.* ; Skyler, J.S.* ; deVries, J.H.* ; Renard, E.* ; Eckel, R.H.* ; Alberti, K.G.M.M.* ; Geloneze, B.* ; Chan, J.C.* ; Mbanya, J.C.* ; Onyegbutulem, H.C.* ; Ramachandran, A.* ; Basit, A.* ; Hassanein, M.T.* ; Bewick, G.A.* ; Spinas, G.A.* ; Beuschlein, F.* ; Landgraf, R.* ; Rubino, F.* ; Mingrone, G.* ; Bornstein, S.R.

COVID-19 and metabolic disease: Mechanisms and clinical management.

Lancet Diabet. Endocrinol. 9, 786-798 (2021)
Postprint DOI PMC
Open Access Green
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Insulin-resistance; Risk-factors; Inflammation; Association; Outcomes; Obesity; Ace2; Mortality; People; Prevention
ISSN (print) / ISBN 2213-8587
e-ISSN 2213-8595
Zeitschrift Lancet Diabetes and Endocrinology
Quellenangaben Band: 9, Heft: 11, Seiten: 786-798 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Ste 800, 230 Park Ave, New York, Ny 10169 Usa
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Pancreatic Beta Cell Research (IPI)
Institute of Experimental Genetics (IEG)
Institute of Diabetes Research and Metabolic Diseases (IDM)
Förderungen DFG
Deutsche Forschungsgemeinschaft, a German Research foundation